aTyr Pharma, Inc. has reported its financial performance for the fiscal year ending December 31, 2025, revealing a net loss of $74.1 million, an increase from a loss of $64.0 million in the previous year. The company's total revenues for 2025 were $0.2 million, a decrease from $0.2 million in 2024, primarily attributed to collaboration revenue from Kyorin Pharmaceutical Co., Ltd. for product material sold to support analytical method validation in Japan. Research and development expenses rose to $60.2 million from $54.4 million, driven by increased costs associated with the development of its lead therapeutic candidate, efzofitimod, and preclinical development efforts.
The company has faced significant challenges, particularly with its EFZO-FIT study, a Phase 3 clinical trial for efzofitimod in patients with pulmonary sarcoidosis, which did not meet its primary endpoint. The study's results indicated a reduction in mean daily oral corticosteroid dose but failed to achieve statistical significance. Despite this, a clinically meaningful improvement was observed in secondary endpoints, including the King's Sarcoidosis Questionnaire-Lung score. Following these results, a Type C meeting with the FDA has been scheduled for mid-April 2026 to discuss the next steps for efzofitimod.
In terms of operational developments, aTyr Pharma's employee count stood at 58 as of December 31, 2025, with all employees based in the United States. The company has also expanded its facilities, increasing its leased space to approximately 24,866 square feet to accommodate its operations. Financially, aTyr Pharma had cash, cash equivalents, and available-for-sale investments totaling $80.9 million at year-end, which the company believes will be sufficient to meet its obligations for at least the next year.
Looking ahead, aTyr Pharma anticipates continued fluctuations in its cash used in operating activities, particularly as it navigates the regulatory landscape and the outcomes of its clinical trials. The company is also exploring additional funding avenues, including equity offerings and collaborations, to support its ongoing research and development efforts. The future of its product candidates, particularly efzofitimod, remains contingent on successful regulatory approvals and market acceptance, which are critical for the company's long-term viability and growth.
About aTYR PHARMA INC
aTyr Pharma, Inc. is a biotechnology company focused on developing therapies for fibrosis and inflammation using its proprietary platform based on extracellular tRNA synthetase biology. Its lead candidate, efzofitimod, is a biologic immunomodulator targeting immune-mediated lung diseases like sarcoidosis and ILD. The company advances novel biologics, collaborates globally, and relies on third-party manufacturing, aiming to address unmet medical needs with innovative, mechanism-based treatments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.